A.O. Krankenhaus St. Josef Braunau GmbH

The Department of Internal Medicine I at A.O. Krankenhaus St. Josef Braunau conducts extensive research focused on preventing and treating major cardiovascular conditions. Studies investigate novel approaches to reducing the risk of cardiovascular death, myocardial infarction, and ischemic stroke in patients with established atherosclerotic cardiovascular disease or those at high cardiovascular risk. Research efforts concentrate on lipid management, particularly targeting elevated lipoprotein(a), and evaluating therapies aimed at reducing serious heart-related complications.

• Prevention of first and recurrent major cardiovascular events in high-risk populations
• Advanced lipid-lowering strategies for atherosclerotic disease management
• Cardiovascular outcome studies in patients with metabolic comorbidities
• Novel therapeutic approaches for reducing cardiovascular mortality

These investigations aim to demonstrate whether emerging treatments can significantly lower the incidence of composite cardiovascular endpoints and improve long-term outcomes in diverse patient populations with varying degrees of cardiovascular risk.

Research at this site addresses the complex relationship between heart failure and chronic kidney disease. Clinical investigations evaluate combination therapies in patients with chronic heart failure and comorbid impairment of kidney function who have experienced recent heart failure events. The studies examine whether novel treatment combinations can reduce the risk of cardiovascular death and heart failure events, including both hospitalizations and urgent visits requiring immediate medical intervention.

• Combination therapy approaches for heart failure with renal impairment
• Prevention of heart failure hospitalizations and cardiovascular death
• Cardiorenal protection strategies in high-risk populations
• Management of patients with recent heart failure decompensation

The research explores whether targeted interventions can address both cardiac and renal dysfunction simultaneously, potentially improving outcomes in this challenging patient population with multiple comorbidities.

The site conducts specialized studies in patients with hypertrophic cardiomyopathy, including both obstructive and non-obstructive forms of the disease. Research focuses on evaluating therapies that may improve patient-reported health status, including symptoms and physical limitations, while also assessing effects on exercise capacity. Investigations utilize advanced cardiac imaging techniques such as cardiac magnetic resonance to measure changes in ventricular wall thickness and atrial size.

• Symptomatic obstructive hypertrophic cardiomyopathy treatment strategies
• Non-obstructive hypertrophic cardiomyopathy therapeutic interventions
• Cardiac structural changes assessed by advanced imaging modalities
• Patient-reported outcomes and exercise capacity improvements

These trials aim to determine whether novel pharmacological approaches can reduce myocardial hypertrophy and improve functional capacity in patients living with this genetic cardiac condition.

Clinical trials at A.O. Krankenhaus St. Josef Braunau investigate treatment options for patients with difficult-to-control blood pressure. Research encompasses both uncontrolled hypertension in patients on dual antihypertensive therapy and resistant hypertension persisting despite treatment with three or more medications at maximum tolerated doses. Studies evaluate the efficacy and safety of novel therapeutic agents in reducing systolic blood pressure in these challenging patient populations.

• Novel mechanisms for blood pressure reduction in resistant hypertension
• Treatment strategies for patients inadequately controlled on multiple agents
• Long-term cardiovascular risk reduction in hypertensive patients
• Safety and tolerability assessment of emerging antihypertensive therapies

The research aims to identify effective interventions for patients whose blood pressure remains elevated despite conventional treatment approaches, potentially reducing their risk of future cardiovascular events.

The department investigates the intersection of metabolic disorders and cardiovascular health, with particular focus on type 2 diabetes, obesity, and overweight conditions. Research evaluates whether metabolic interventions can reduce major adverse cardiovascular events while also addressing weight management and glycemic control. Studies examine therapies designed to prevent serious heart-related complications and kidney function deterioration in patients with metabolic disease.

• Cardiovascular outcome trials in patients with type 2 diabetes and obesity
• Weight reduction strategies with cardiovascular benefits
• Prevention of kidney function worsening in metabolic disease
• Non-inferiority and superiority studies comparing novel agents to standard therapies

These investigations seek to determine whether addressing metabolic abnormalities can simultaneously improve cardiovascular outcomes and preserve renal function in high-risk populations.

Research efforts include studies focused on transthyretin amyloidosis with cardiomyopathy, a progressive disease characterized by abnormal protein deposition in cardiac tissue. Clinical trials evaluate novel therapeutic approaches aimed at reducing all-cause mortality and cardiovascular events in patients with this condition. The investigations assess whether targeted interventions can alter disease progression and improve survival outcomes.

• Disease-modifying therapies for cardiac amyloidosis
• Mortality reduction strategies in ATTR cardiomyopathy
• Prevention of cardiovascular events in amyloid heart disease
• Long-term efficacy assessment in progressive cardiac conditions

The research aims to establish effective treatments for this previously difficult-to-treat condition, potentially offering hope to patients with this serious cardiac disorder.

The site conducts respiratory research focusing on chronic obstructive pulmonary disease and its cardiovascular implications. Studies evaluate combination inhaled therapies, including triple therapy with bronchodilators and corticosteroids, compared to dual bronchodilator approaches. The research examines effects on severe cardiopulmonary outcomes, recognizing the significant cardiovascular burden associated with advanced COPD.

• Triple versus dual therapy efficacy in COPD management
• Cardiopulmonary outcome prevention in chronic respiratory disease
• Bronchodilator and anti-inflammatory combination strategies
• Reduction of severe respiratory and cardiovascular complications

These investigations aim to determine optimal therapeutic approaches that address both respiratory symptoms and cardiovascular complications in patients with chronic obstructive pulmonary disease.

Clinical trials investigate pulmonary hypertension in patients with heart failure with preserved ejection fraction. Research evaluates therapies designed to improve exercise limitation, measured by changes in six-minute walk distance, while assessing safety and tolerability. The studies focus on patients experiencing functional impairment due to the combination of elevated pulmonary pressures and preserved left ventricular systolic function.

• Exercise capacity improvement in PH-HFpEF patients
• Functional outcome measures in pulmonary hypertension
• Novel therapeutic mechanisms for combined cardiopulmonary disease
• Safety assessment in complex heart failure phenotypes

The research addresses an important subset of heart failure patients who experience significant exercise intolerance due to elevated pulmonary pressures despite maintained cardiac contractility.